Divestments

CaridianBCT

After Gambro AB was acquired in 2006 by EQT IV and Investor AB, Gambro (dialysis), CaridianBCT (blood technology) and the clinics business Gambro Healthcare were separated. CaridianBCT was thereafter managed as an independent company.

During EQT’s and Investor’s ownership, R&D investments were significant leading to CaridianBCT strengthening its position in the important growth areas of Pathogen Reduction and Whole Blood Processing.

  • Sektor
    Healthcare
  • Land
    United States
  • Fond
    EQT IV
  • Entry
    2006
  • Exit
    2011-04-01

The roll-out of several new products like the Spectra Optia Apheresis System and the Quantum Cell Expansion System during the ownership period will be important future growth drivers.

In 2011, EQT IV signed an agreement to sell CaridianBCT to the Japanese medical technology company Terumo Corporation for a total enterprise value of USD 2,625 m. CaridianBCT was at the time of the sale a world leading global provider of technology, products and services in automated blood collection, therapeutic systems, whole blood processes and pathogen reduction technologies.

Prenumerera

Prenumerera på EQT:s press releaser, regulatoriska press releaser och updates.

Typ av nyheter
Preferred language
EQT logo
En syftesdriven global investeringsorganisation
© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180